Maynard Um
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Actuate Therapeutics (ACTU)
-
-
-
-
-
-
-
Actuate Therapeutics publishes phase II salivary gland cancer data
-
-
-
-
-
-
-
Actuate Therapeutics (ACTU) Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial
-
-
-
-
-
-
-
Actuate Therapeutics (ACTU) Announces FDA Rare Pediatric Disease Designation Granted to Elraglusib for Treatment of Ewing Sarcoma
-
-
-
-
-
439,164 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

